Esophageal and Gastrosophageal Junction (GEJ) Cancer 2025 UPDATE
Two Onc Docs
00:00
Second-line Options for Metastatic Disease
They discuss using immunotherapy if not given upfront, taxanes, single-agent chemotherapies, and HER2-targeted agents in HER2-positive adenocarcinoma.
Play episode from 13:19
Transcript
